{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-003903","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.995651+00:00","generated_at":"2026-06-06T23:03:42.153278+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protagonist details rusfertide Ph3 enrollment, JNJ-2113 milestones, cash runway through Q1 2026","bullets":["Rusfertide VERIFY Ph3 enrollment expected to complete 1Q24; NDA filing planned for Q4 2024.","JNJ-2113 ICONIC Ph3 program ongoing; ANTHEM UC Ph2b expected completion ~May 2025.","Oral IL-17 peptide antagonist development candidate on track for 2024.","Cash runway forecast through Q1 2026; $215M potential milestones from Janssen not included.","$172.5M in upfront and development milestones achieved, including $60M in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-003903","json":"https://secwatch.observer/filing/0001104659-24-003903.json","markdown":"https://secwatch.observer/filing/0001104659-24-003903.md","text":"https://secwatch.observer/filing/0001104659-24-003903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924003903/0001104659-24-003903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924003903/tm243318d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:03:42.153278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}